Bajetta E, Buzzoni R, Viviani S, Vaglini M, Nava M, Bonadonna G
Am J Clin Oncol. 1985 Oct;8(5):401-5. doi: 10.1097/00000421-198510000-00012.
Thirty-seven consecutive patients with disseminated malignant melanoma and previously untreated with chemotherapy were randomly allocated to receive vindesine, cis-platinum, and etoposide (Regimen A) or vindesine, cis-platinum, and lomustine (Regimen B). In 31 evaluable patients, Regimen A induced an overall response rate of 31% and a complete response rate of 6%; with Regimen B the corresponding findings were 20% and 20%, respectively. The median duration of complete response was 12 months with both regimens and the comparative median total survivals were 8 and 6 months, respectively. In no case was toxicity so severe to require treatment discontinuation, and the major dose-limiting side effect was myelosuppression, especially in the patients treated with Regimen B. Present results confirm once more the limited activity of drugs and regimens presently utilized in the treatment of advanced malignant melanoma.
37例连续的播散性恶性黑色素瘤患者，此前未接受过化疗，被随机分配接受长春地辛、顺铂和依托泊苷（方案A）或长春地辛、顺铂和洛莫司汀（方案B）治疗。在31例可评估患者中，方案A诱导的总缓解率为31%，完全缓解率为6%；方案B的相应结果分别为20%和20%。两种方案的完全缓解中位持续时间均为12个月，比较的总生存中位时间分别为8个月和6个月。在任何情况下，毒性都没有严重到需要停药的程度，主要的剂量限制性副作用是骨髓抑制，尤其是在接受方案B治疗的患者中。目前的结果再次证实了目前用于治疗晚期恶性黑色素瘤的药物和方案活性有限。
